BNTX News & Analysis
2 articles
Market Mood
BMY vs JNJ: Healthcare Revenue Comparison for 2025
In fiscal 2025, Bristol Myers Squibb (BMY) reported revenue of nearly $48.2 billion, a decrease of approximately 0.2% from the previous year, with a net income of roughly $7.1 billion and a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved approximately $94.2 billion in revenue, reflecting an increase of nearly 6% year-over-year, accompanied by a net income of around $26.8 billion and a net margin of 28.5%. BMY's balance sheet showed a debt-to-equity ratio of 2.6 and a current ratio of 1.3, while its free cash flow reached nearly $12.8 billion. These figures underscore the differing financial health and revenue growth trajectories of these two healthcare companies.
Read More
BioNTech (BNTX) Schedules Annual Meeting for May 15, 2026
BioNTech (BNTX) has announced that its annual general meeting will take place on May 15, 2026. This meeting is significant as it will provide updates on the company's performance and future strategic directions. Investors often look forward to these meetings for insights that could impact stock performance. The scheduled date could have implications for market sentiment leading up to the event.
Read More